Among the PD-1 inhibitors, pembrolizumab showed the broadest spectrum of hematologic and lymphatic AEs, with 41 PTs detected as signals, ranging from aplastic anemia (ROR025: 1.06) to immune-mediated cytopenia (ROR025: 131.29). Here, PDCD1 is linked to aplastic anemia.